Improvement of drug safety by the use of lipid-based nanocarriers

Journal of Controlled Release

Volumn 163, Issue 1, 2012, Pages 34-45

  Lim, Sok Bee ^a   Banerjee, Amrita ^a   Önyüksel, Hayat ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University of Illinois at Chicago   (United States)

Author keywords

Drug safety; Lipid nanocarriers; Liposomes; Micelles; Solid lipid nanoparticle

Indexed keywords

ACTIVE TARGETING; AQUEOUS MEDIA; BIODISTRIBUTIONS; BLOOD COMPONENT; COSOLVENTS; DELIVERY SYSTEMS; DOSE-DEPENDENT; DRUG FORMULATIONS; DRUG SAFETY; ENZYMATIC DEGRADATION; HUMAN BODIES; HYDROPHOBIC DRUG; IMMUNOGENICITY; NANO-EMULSIONS; NANO-SUSPENSIONS; NANOCARRIERS; PH ADJUSTMENT; PHARMACEUTICAL PRODUCTS; SOLID LIPID NANOPARTICLE (SLN); TARGET SITES; THERAPEUTIC DOSE;

ENZYME INHIBITION; LIPOSOMES; MICELLES; NANOPARTICLES; PATIENT TREATMENT; TISSUE; TOXICITY;

DRUG PRODUCTS;

CAMPTOTHECIN; DOXORUBICIN; DRUG CARRIER; ETOPOSIDE; FIBRINOGEN; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; LIPOSOME; MONOCLONAL ANTIBODY; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PHOSPHOLIPID; SILICON DIOXIDE; SOLID LIPID NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; BREAST CANCER; CARDIOTOXICITY; CONFERENCE PAPER; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; IMMUNOGENICITY; MICELLE; NANOEMULSION; NONHUMAN; PH; PHAGOCYTE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SUSPENSION; TUMOR LOCALIZATION;

ANIMALS; DRUG CARRIERS; DRUG STABILITY; DRUG TOXICITY; HUMANS; LIPIDS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84866737577     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.06.002     Document Type: Conference Paper

References (144)

1. I. Ojima Medicinal chemistry at a crossroads: challenges and new possibilities Future Med. Chem. 1 2009 401 403
2. J. Splawinski, J. Kuzniar, K. Filipiak, and W. Zielinski Evaluation of drug toxicity in clinical trials Sci. Eng. Ethics 12 2006 139 145
3. S. Okie Safety in numbers - monitoring risk in approved drugs N. Engl. J. Med. 352 2005 1173 1176
4. J.M. Brophy Cardiovascular effects of cyclooxygenase-2 inhibitors Curr. Opin. Gastroenterol. 23 2007 617 624
5. S. Bunniran, D.J. McCaffrey III, J.P. Bentley, and A.S. Bouldin Pharmaceutical product withdrawal: attributions of blame and its impact on trust Res. Soc. Adm. Pharm. 5 2009 262 273
6. T.J. Moore, M.R. Cohen, and C.D. Furberg Serious adverse drug events reported to the food and drug administration, 1998-2005 Arch. Intern. Med. 167 2007 1752 1759
7. L.H. Reddy Drug delivery to tumours: recent strategies J. Pharm. Pharmacol. 57 2005 1231 1242
8. R. Soloman, and A.A. Gabizon Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin Clin. Lymphoma Myeloma 8 2008 21 32
9. G. Vassal, C. Pondarré, I. Boland, C. Cappelli, A. Santos, C. Thomas, E. Lucchi, K. Imadalou, F. Pein, J. Morizet, and A. Gouyette Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology Biochimie 80 1998 271 280
10. M. Marangolo, C. Bengala, P.F. Conte, M. Danova, P. Pronzato, G. Rosti, and P. Sagrada Dose and outcome: the hurdle of neutropenia (review) Oncol. Rep. 16 2006 233 248
11. N. Lamanna, and M.A. Weiss Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia Semin. Hematol. 43 Suppl. 2 2006 S44 S49
12. G. Metro, A. Fabi, M. Russillo, P. Papaldo, M. De Laurentiis, G. Ferretti, D. Pellegrini, C. Nuzzo, V. Graziano, P. Vici, M. Introna, A. Felici, F. Cognetti, and P. Carlini Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule Anticancer. Res. 28 2008 1245 1258
13. S.M. Swain, and J.C. Arezzo Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management Clin. Adv. Hematol. Oncol. 6 2008 455 467
14. A.J. ten Tije, J. Verweij, W.J. Loos, and A. Sparreboom Pharmacological effects of formulation vehicles: implications for cancer chemotherapy Clin. Pharmacokinet. 42 2003 665 685
15. M.J. Hawkins, P. Soon-Shiong, and N. Desai Protein nanoparticles as drug carriers in clinical medicine Adv. Drug Deliv. Rev. 60 2008 876 885
16. F. Locatelli, L. Del Vecchio, and P. Pozzoni Pure red-cell aplasia epidemic - mystery completely revealed? Perit. Dial. Int. 27 Suppl. 2 2007 S303 S307
17. H. Schellekens Factors influencing the immunogenicity of therapeutic proteins Nephrol. Dial. Transplant. 20 Suppl. 6 2005 vi3 vi9
18. P. Simamora, S. Pinsuwan, J.M. Alvarez, P.B. Myrdal, and S.H. Yalkowsky Effect of pH on injection phlebitis J. Pharm. Sci. 84 1995 520 522
19. J.L. Johnson, and S.H. Yalkowsky Reformulation of a new vancomycin analog: an example of the importance of buffer species and strength AAPS PharmSciTech 7 2006 E5
20. H. Onyuksel, F. Sejourne, H. Suzuki, and I. Rubinstein Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension Peptides 27 2006 2271 2275
21. M. Rawat, D. Singh, S. Saraf, and S. Saraf Lipid carriers: a versatile delivery vehicle for proteins and peptides Yakugaku Zasshi 128 2008 269 280
22. P.P. Constantinides, M.V. Chaubal, and R. Shorr Advances in lipid nanodispersions for parenteral drug delivery and targeting Adv. Drug Deliv. Rev. 60 2008 757 767
23. V.P. Torchilin Micellar nanocarriers: pharmaceutical perspectives Pharm. Res. 24 2007 1 16
24. B. Ashok, L. Arleth, R.P. Hjelm, I. Rubinstein, and H. Onyuksel In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation J. Pharm. Sci. 93 2004 2476 2487
25. S. Martins, B. Sarmento, D.C. Ferreira, and E.B. Souto Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles Int. J. Nanomedicine 2 2007 595 607
26. D.K. Sarker Engineering of nanoemulsions for drug delivery Curr. Drug Deliv. 2 2005 297 310
27. A. Krishnadas, I. Rubinstein, and H. Onyuksel Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs Pharm. Res. 20 2003 297 302
28. A. Samad, Y. Sultana, and M. Aqil Liposomal drug delivery systems: an update review Curr. Drug Deliv. 4 2007 297 305
29. S.P. Vyas, and S. Gupta Optimizing efficacy of amphotericin B through nanomodification Int. J. Nanomedicine 1 2006 417 432
30. K.L. Hennenfent, and R. Govindan Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 17 2006 735 749
31. N. Tang, G. Du, N. Wang, C. Liu, H. Hang, and W. Liang Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin J. Natl. Cancer Inst. 99 2007 1004 1015
32. O.M. Koo, I. Rubinstein, and H. Onyuksel Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis Pharm. Res. 28 2011 776 787
33. H. Onyuksel, H. Ikezaki, M. Patel, X.P. Gao, and I. Rubinstein A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo Pharm. Res. 16 1999 155 160
34. M.N. Sahib, Y. Darwis, K.K. Peh, S.A. Abdulameer, and Y.T. Tan Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations Int. J. Nanomedicine 6 2011 2351 2366
35. J. Ye, Q. Wang, X. Zhou, and N. Zhang Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis Int. J. Pharm. 352 2008 273 279
36. L. Harivardhan Reddy, R.K. Sharma, K. Chuttani, A.K. Mishra, and R.S.R. Murthy Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in dalton's lymphoma tumor bearing mice J. Control. Release 105 2005 185 198
37. M.O. Oyewumi, R.A. Yokel, M. Jay, T. Coakley, and R.J. Mumper Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice J. Control. Release 95 2004 613 626
38. Y. Waknine FDA approvals: nascobal nasal spray, PTC 124, tocosol paclitaxel Medscape Med. News Feb 03, 2005
39. K.K. Singh, and S.K. Vingkar Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine Int. J. Pharm. 347 2008 136 143
40. E. Olavarria, M. Hassan, A. Eades, C. Nilsson, A. Timms, J. Matthews, C. Craddock, E. Kanfer, J. Apperley, and J. Goldman A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation Leukemia 14 2000 1954 1959
41. K. Peters, S. Leitzke, J.E. Diederichs, K. Borner, H. Hahn, R.H. Muller, and S. Ehlers Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection J. Antimicrob. Chemother. 45 2000 77 83
42. M.J. Copland, T. Rades, N.M. Davies, and M.A. Baird Lipid based particulate formulations for the delivery of antigen Immunol. Cell Biol. 83 2005 97 105
43. O.M. Koo, I. Rubinstein, and H. Onyuksel Role of nanotechnology in targeted drug delivery and imaging: a concise review Nanomed. Nanotechnol. Biol. Med. 1 2005 193 212
44. K. Jain, P. Kesharwani, U. Gupta, and N.K. Jain Dendrimer toxicity: let's meet the challenge Int. J. Pharm. 394 2010 122 142
45. K. Kostarelos The long and short of carbon nanotube toxicity Nat. Biotechnol. 26 2008 774 776
46. C.M. Goodman, C.D. McCusker, T. Yilmaz, and V.M. Rotello Toxicity of gold nanoparticles functionalized with cationic and anionic side chains Bioconjug. Chem. 15 2004 897 900
47. S.J. Soenen, and M. De Cuyper Assessing iron oxide nanoparticle toxicity in vitro: current status and future prospects Nanomedicine (Lond.) 5 2010 1261 1275
48. Y.L. Hu, W. Qi, F. Han, J.Z. Shao, and J.Q. Gao Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model Int. J. Nanomedicine 6 2011 3351 3359
49. G. Cevc Phospholipids Handbook 1993 Marcel Dekker Inc. New York, USA
50. M.A. Crook Lipid clearance and total parenteral nutrition: the importance of monitoring plasma lipids Nutrition 16 2000 774 775
51. M.C. Pedroso de Lima, S. Neves, A. Filipe, N. Duzgunes, and S. Simoes Cationic liposomes for gene delivery: from biophysics to biological applications Curr. Med. Chem. 10 2003 1221 1231
52. S.C. Semple, A. Chonn, and P.R. Cullis Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo Adv. Drug Deliv. Rev. 32 1998 3 17
53. S.M. Moghimi, A.J. Andersen, S.H. Hashemi, B. Lettiero, D. Ahmadvand, A.C. Hunter, T.L. Andresen, I. Hamad, and J. Szebeni Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead J. Control. Release 146 2010 175 181
54. I. Hamad, A.C. Hunter, J. Szebeni, and S.M. Moghimi Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process Mol. Immunol. 46 2008 225 232
55. M.R. Sherman, L.D. Williams, M.A. Sobczyk, S.J. Michaels, and M.G. Saifer Role of the methoxy group in immune responses to mPEG-protein conjugates Bioconjug. Chem. 23 2012 485 499
56. M. Ohnish, and H. Sagitani The effect of nonionic surfactant structure on hemolysis J. Am. Oil Chem. Soc. 70 1993 297 305
57. M.A. Partearroyo, H. Ostolaza, F.M. Goñi, and E. Barberá-Guillem Surfactant-induced cell toxicity and cell lysis: a study using B16 melanoma cells Biochem. Pharmacol. 40 1990 1323 1328
58. J. Wong, A. Brugger, A. Khare, M. Chaubal, P. Papadopoulos, B. Rabinow, J. Kipp, and J. Ning Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects Adv. Drug Deliv. Rev. 60 2008 939 954
59. H. Onyuksel, P.S. Mohanty, and I. Rubinstein VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer Int. J. Pharm. 365 2009 157 161
60. H. Cesur, I. Rubinstein, A. Pai, and H. Onyuksel Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer Nanomedicine 5 2009 178 183
61. R.R. Sawant, R.M. Sawant, and V.P. Torchilin Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity Eur. J. Pharm. Biopharm. 70 2008 51 57
62. G.A. Peyman, B. Khoobehi, M. Tawakol, J.A. Schulman, H.A. Mortada, H. Alkan, and R. Fiscella Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model Retina 7 1987 227 229
63. E. Ojewole, I. Mackraj, P. Naidoo, and T. Govender Exploring the use of novel drug delivery systems for antiretroviral drugs Eur. J. Pharm. Biopharm. 70 2008 697 710
64. X. Yang, X. Zhao, M.A. Phelps, L. Piao, D.M. Rozewski, Q. Liu, L.J. Lee, G. Marcucci, M.R. Grever, J.C. Byrd, J.T. Dalton, and R.J. Lee A novel liposomal formulation of flavopiridol Int. J. Pharm. 365 2009 170 174
65. S.C. Yang, L.F. Lu, Y. Cai, J.B. Zhu, B.W. Liang, and C.Z. Yang Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain J. Control. Release 59 1999 299 307
66. S. Lim, M. Lee, and C. Kim Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders J. Control. Release 100 2004 53 61
67. Y. Gupta, A. Jain, and S.K. Jain Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain J. Pharm. Pharmacol. 59 2007 935 940
68. K. Manjunath, and V. Venkateswarlu Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration J. Control. Release 107 2005 215 228
69. F. Podlogar, M. Gašperlin, M. Tomšič, A. Jamnik, and M.B. Rogač Structural characterisation of water - Tween 40®/Imwitor 308®-isopropyl myristate microemulsions using different experimental methods Int. J. Pharm. 276 2004 115 128
70. J.B. Tagne, S. Kakumanu, and R.J. Nicolosi Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model Mol. Pharm. 5 2008 1055 1063
71. J.B. Tagne, S. Kakumanu, D. Ortiz, T. Shea, and R.J. Nicolosi A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line Mol. Pharm. 5 2008 280 286
72. B.E. Rabinow Nanosuspensions in drug delivery Nat. Rev. Drug Discov. 3 2004 785 796
73. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830
74. A. Krishnadas, H. Onyuksel, and I. Rubinstein Interactions of VIP, secretin and PACAP(1-38) with phospholipids: a biological paradox revisited Curr. Pharm. Des. 9 2003 1005 1012
75. S. Gandhi, T. Tsueshita, H. Onyuksel, R. Chandiwala, and I. Rubinstein Interactions of human secretin with sterically stabilized phospholipid micelles amplify peptide-induced vasodilation in vivo Peptides 23 2002 1433 1439
76. S.B. Lim, I. Rubinstein, and H. Onyuksel Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles Int. J. Pharm. 356 2008 345 350
77. B. Ashok, I. Rubinstein, T. Tsueshita, and H. Onyuksel Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP1-38 in pegylated phospholipid micelles Peptides 25 2004 1253 1258
78. S. Dagar, H. Onyuksel, S. Akhter, A. Krishnadas, and I. Rubinstein Human galanin expresses amphipathic properties that modulate its vasoreactivity in vivo Peptides 24 2003 1373 1380
79. A. Banerjee, and H. Onyuksel Human pancreatic polypeptide in a phospholipid based micellar formulation Pharm. Res. 29 2012 1698 1711
80. A. Kuzmis, S.B. Lim, E. Desai, E. Jeon, B. Lee, I. Rubinstein, and H. Onyuksel Micellar nanomedicine of human neuropeptide Y Nanomed. Nanotechnol. Biol. Med. 7 2011 464 471
81. S. Onoue, A. Matsumoto, Y. Nagano, K. Ohshima, Y. Ohmori, S. Yamada, R. Kimura, T. Yajima, and K. Kashimoto α-Helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences Eur. J. Pharmacol. 485 2004 307 316
82. V. Manojlovic, K. Winkler, V. Bunjes, A. Neub, R. Schubert, B. Bugarski, and G. Leneweit Membrane interactions of ternary phospholipid/cholesterol bilayers and encapsulation efficiencies of a RIP II protein Colloids Surf., B 64 2008 284 296
83. F. Hajos, B. Stark, S. Hensler, R. Prassl, and W. Mosgoeller Inhalable liposomal formulation for vasoactive intestinal peptide Int. J. Pharm. 357 2008 286 294
84. V. Sethi, H. Onyuksel, I. Rubinstein, Liposomal vasoactive intestinal peptide, in: Methods in Enzymology, vol. 391, Academic Press, 2005, pp. 377-395.
85. J.S. Powell, D.J. Nugent, J.A. Harrison, A. Soni, A. Luk, H. Stass, and E. Gorina Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A J. Thromb. Haemost. 6 2008 277 283
86. I. Rubinstein, H. Ikezaki, and H. Onyuksel Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters Int. J. Pharm. 316 2006 144 147
87. R.H. Müller, S.A. Runge, V. Ravelli, A.F. Thünemann, W. Mehnert, and E.B. Souto Cyclosporine-loaded solid lipid nanoparticles (SLN®): drug-lipid physicochemical interactions and characterization of drug incorporation Eur. J. Pharm. Biopharm. 68 2008 535 544
88. A.J. Almeida, and E. Souto Solid lipid nanoparticles as a drug delivery system for peptides and proteins Adv. Drug Deliv. Rev. 59 2007 478 490
89. B. Sarmento, S. Martins, D. Ferreira, and E.B. Souto Oral insulin delivery by means of solid lipid nanoparticles Int. J. Nanomedicine 2 2007 743 749
90. S.A. Wissing, O. Kayser, and R.H. Müller Solid lipid nanoparticles for parenteral drug delivery Adv. Drug Deliv. Rev. 56 2004 1257 1272
91. W. Ge, Y. Li, Z.S. Li, S.H. Zhang, Y.J. Sun, P.Z. Hu, X.M. Wang, Y. Huang, S.Y. Si, X.M. Zhang, and Y.F. Sui The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route Cancer Immunol. Immunother. 58 2009 201 208
92. A.S. Pattani, S.D. Mandawgade, and V.B. Patravale Development and comparative anti-microbial evaluation of lipid nanoparticles and nanoemulsion of polymyxin B J. Nanosci. Nanotechnol. 6 2006 2986 2990
93. Y. Namiki, T. Namiki, M. Date, K. Yanagihara, M. Yashiro, and H. Takahashi Enhanced photodynamic antitumor effect on gastric cancer by a novel photosensitive stealth liposome Pharmacol. Res. 50 2004 65 76
94. J.X. Zhang, C.B. Hansen, T.M. Allen, A. Boey, and R. Boch Lipid-derivatized poly(ethylene glycol) micellar formulations of benzoporphyrin derivatives J. Control. Release 86 2003 323 338
95. I. Skidan, P. Dholakia, and V. Torchilin Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20- tetraphenylporphin-loaded PEG-PE micelles J. Drug Target. 16 2008 486 493
96. L.O. Cinteza, T.Y. Ohulchanskyy, Y. Sahoo, E.J. Bergey, R.K. Pandey, and P.N. Prasad Diacyllipid micelle-based nanocarrier for magnetically guided delivery of drugs in photodynamic therapy Mol. Pharm. 3 2006 415 423
97. N. Fomina, J. Sankaranarayanan, and A. Almutairi Photochemical mechanisms of light-triggered release from nanocarriers Adv. Drug Deliv. Rev. 64 2012 1005 1020
98. M.E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D.G. Kieback, P. Tomczak, S.P. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler CAELYX Breast Cancer Study Group Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449
99. G. Batist, G. Ramakrishnan, C.S. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, P. Shah, A. Khojasteh, M.K. Nair, K. Hoelzer, K. Tkaczuk, Y.C. Park, and L.W. Lee Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer J. Clin. Oncol. 19 2001 1444 1454
100. Etoposide official FDA information side effects and uses Available from: http://www.drugs.com/pro/etoposide.html
101. M.D. Joshi, and R.H. Müller Lipid nanoparticles for parenteral delivery of actives Eur. J. Pharm. Biopharm. 71 2009 161 172
102. C.E. Ashley, E.C. Carnes, G.K. Phillips, D. Padilla, P.N. Durfee, P.A. Brown, T.N. Hanna, J. Liu, B. Phillips, M.B. Carter, N.J. Carroll, X. Jiang, D.R. Dunphy, C.L. Willman, D.N. Petsev, D.G. Evans, A.N. Parikh, B. Chackerian, W. Wharton, D.S. Peabody, and C.J. Brinker The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers Nat. Mater. 10 2011 389 397
103. I. Rubinstein, I. Soos, and H. Onyuksel Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells Chem. Biol. Interact. 171 2008 190 194
104. H. Onyuksel, E. Jeon, and I. Rubinstein Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells Cancer Lett. 274 2009 327 330
105. S. Dagar, A. Krishnadas, I. Rubinstein, M.J. Blend, and H. Onyuksel VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: In vivo studies J. Control. Release 91 2003 123 133
106. J.F. Lovell, C.S. Jin, E. Huynh, H. Jin, C. Kim, J.L. Rubinstein, W.C. Chan, W. Cao, L.V. Wang, and G. Zheng Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents Nat. Mater. 10 2011 324 332
107. A. Allegra, G. Penna, A. Alonci, V. Rizzo, S. Russo, and C. Musolino Nanoparticles in oncology: the new theragnostic molecules Anticancer Agents Med. Chem. 11 2011 669 686
108. E. Gonzalez-Rey, N. Varela, A. Chorny, and M. Delgado Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator Curr. Pharm. Des. 13 2007 1113 1139
109. A. Béduneau, P. Saulnier, and J. Benoit Active targeting of brain tumors using nanocarriers Biomaterials 28 2007 4947 4967
110. S.M. Demos, S. Dagar, M. Klegerman, A. Nagaraj, D.D. McPherson, and H. Onyuksel In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions J. Drug Target. 5 1998 507 518
111. T.A. Elbayoumi, and V.P. Torchilin Tumor-specific antibody-mediated targeted delivery of doxil® reduces the manifestation of auricular erythema side effect in mice Int. J. Pharm. 357 2008 272 279
112. D. Goldstein, O. Gofrit, A. Nyska, and S. Benita Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer Cancer Res. 67 2007 269 275
113. A. Lutterotti, and R. Martin Getting specific: monoclonal antibodies in multiple sclerosis Lancet Neurol. 7 2008 538 547
114. P.L. Myskowski, and A.C. Halpern Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer Curr. Allergy Asthma Rep. 8 2008 63 68
115. R.M. Sawant, J.P. Hurley, S. Salmaso, A. Kale, E. Tolcheva, T.S. Levchenko, and V.P. Torchilin "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers Bioconjug. Chem. 17 2006 943 949
116. V. Torchilin Multifunctional and stimuli-sensitive pharmaceutical nanocarriers Eur. J. Pharm. Biopharm. 71 2009 431 444
117. S. Ganta, H. Devalapally, A. Shahiwala, and M. Amiji A review of stimuli-responsive nanocarriers for drug and gene delivery J. Control. Release 126 2008 187 204
118. H. Shmeeda, L. Mak, D. Tzemach, P. Astrahan, M. Tarshish, and A. Gabizon Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors Mol. Cancer Ther. 5 2006 818 824
119. Y. Gupta, A. Jain, P. Jain, and S.K. Jain Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells J. Drug Target. 15 2007 231 240
120. L.A. Pires, R. Hegg, C.J. Valduga, S.R. Graziani, D.G. Rodrigues, and R.C. Maranhao Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study Cancer Chemother. Pharmacol. 63 2009 281 287
121. J.D. Glickson, S. Lund-Katz, R. Zhou, H. Choi, I.W. Chen, H. Li, I. Corbin, A.V. Popov, W. Cao, L. Song, C. Qi, D. Marotta, D.S. Nelson, J. Chen, B. Chance, and G. Zheng Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents Mol. Imaging 7 2008 101 110
122. X. Guo, F. Cui, Y. Xing, Q. Mei, and Z. Zhang Investigation of a new injectable thermosensitive hydrogel loading solid lipid nanoparticles Pharmazie 66 2011 948 952
123. J. Szebeni, L. Baranyi, S. Savay, M. Bodo, D.S. Morse, M. Basta, G.L. Stahl, R. Bunger, and C.R. Alving Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction Am. J. Physiol. Heart Circ. Physiol. 279 2000 H1319 H1328
124. P. Aggarwal, J.B. Hall, C.B. McLeland, M.A. Dobrovolskaia, and S.E. McNeil Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy Adv. Drug Deliv. Rev. 61 2009 428 437
125. M. Lundqvist, J. Stigler, G. Elia, I. Lynch, T. Cedervall, and K.A. Dawson Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts Proc. Natl. Acad. Sci. U. S. A. 105 2008 14265 14270
126. A.S. Zahr, C.A. Davis, and M.V. Pishko Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol) Langmuir 22 2006 8178 8185
127. D. Bhadra, S. Bhadra, P. Jain, and N.K. Jain Pegnology: a review of PEG-ylated systems Pharmazie 57 2002 5 29
128. S.S. Yu, C.M. Lau, S.N. Thomas, W.G. Jerome, D.J. Maron, J.H. Dickerson, J.A. Hubbell, and T.D. Giorgio Size and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages Int. J. Nanomedicine 2012 2012 799 813
129. M. Eugene Polyethyleneglycols and immunocamouflage of the cells tissues and organs for transplantation Cell. Mol. Biol. (Noisy-le-grand) 50 2004 209 215
130. M.G. Pegylation Engineering improved pharmaceuticals for enhanced therapy Cancer Treat. Rev. 28 Suppl. 1 2002 13 16
131. C.M. Lee, Y. Choi, E.J. Huh, K.Y. Lee, H.C. Song, M.J. Sun, H.J. Jeong, C.S. Cho, and H.S. Bom Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation Cancer Biother. Radiopharm. 20 2005 620 628
132. J. Rossi, S. Giasson, M.N. Khalid, P. Delmas, C. Allen, and J. Leroux Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors Eur. J. Pharm. Biopharm. 67 2007 329 338
133. J.R. Robinson, and V.H. Lee Controlled Drug Delivery: Fundamentals and Applications 2nd ed. 1993 Marcel Dekker, Inc. New York, USA
134. J.M. Harris, N.E. Martin, and M. Modi Pegylation: a novel process for modifying pharmacokinetics Clin. Pharmacokinet. 40 2001 539 551
135. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318
136. A.N. Lukyanov, and V.P. Torchilin Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs Adv. Drug Deliv. Rev. 56 2004 1273 1289
137. R.R. Sawant, R.M. Sawant, A.A. Kale, and V.P. Torchilin The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells J. Drug Target. 16 2008 596 600
138. R.L. Nation, A.M. Evans, and R.W. Milne Pharmacokinetic drug interactions with phenytoin (part I) Clin. Pharmacokinet. 18 1990 37 60
139. J.C. McElnay, and P.F. D'Arcy Protein binding displacement interactions and their clinical importance Drugs 25 1983 495 513
140. R. Zini, P. Riant, J. Barre, and J.P. Tillement Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (part I) Clin. Pharmacokinet. 19 1990 147 159
141. H. Heiati, R. Tawashi, and N.C. Phillips Solid lipid nanoparticles as drug carriers: II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3′-azido-3′- deoxythymidine palmitate in mice Int. J. Pharm. 174 1998 71 80
142. A.H. Sehon, and G.M. Lang Avoiding untoward immune responses to novel gene products J. Liposome Res. 12 2002 199 204
143. A.M. Chen, and M.D. Scott Current and future applications of immunological attenuation via pegylation of cells and tissue BioDrugs 15 2001 833 847
144. S. Naik, M. Chougule, B.K. Padhi, and A. Misra Development of novel lyophilized mixed micelle amphotericin B formulation for treatment of systemic fungal infection Curr. Drug Deliv. 2 2005 177 184